Clinical trial
A Phase III, Multicenter, Randomized, Open-Label, Parallel-Controlled Clinical Trial to Evaluate the Efficacy and Safety of Once-Weekly SHR-3167 Compared With Once-Daily Insulin Glargine in Adults With Insulin-Naive Type 2 Diabetes
NCT07920939 is registered in ClinicalTrials.gov with Jiangsu HengRui Medicine Co., Ltd. as lead sponsor.
Search trials, sites, companies and investigators, and follow each one to the others. Individual plan, 14-day trial. Card required. Your first charge is when the trial ends. See pricing
Registry record
As filed in ClinicalTrials.gov.
- Title
- A Phase III, Multicenter, Randomized, Open-Label, Parallel-Controlled Clinical Trial to Evaluate the Efficacy and Safety of Once-Weekly SHR-3167 Compared With Once-Daily Insulin Glargine in Adults With Insulin-Naive Type 2 Diabetes
- Lead sponsor
- Jiangsu HengRui Medicine Co., Ltd.
- Phase
- Phase 3
- Overall status
- Not yet recruiting
- Start date
- November 30, 2026
- Completion date
- July 31, 2028
- Enrollment
- 450 (estimated)
- Sites
- 2
Conditions
As the registry lists them; a condition with its own page is linked.
type 2 diabetes
Lead sponsor's other trials
Jiangsu HengRui Medicine Co., Ltd., most recent start first.
+567 more trials See the organization page
Similar trials
Same condition (Diabetes Mellitus, Type 2) and phase, most recent start first.
+1,316 more trials See the condition page